Trial · NCT07905625
Effect of Early Tendon Vibrations on Upper Limb Motor Recovery After a Stroke
NCT07905625, Not applicable, Not yet recruiting, Centre Hospitalier Régional d'Orléans
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Early Tendon Vibrations on Upper Limb Motor Recovery After a Stroke. Trials, record NCT07905625. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07905625
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Early Tendon Vibrations on Upper Limb Motor Recovery After a Stroke
- NCT number
- NCT07905625
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 54 participants, estimated
- Lead sponsor
- Centre Hospitalier Régional d'Orléans
- Conditions
- Acute Stroke, Upper Limb Motor Deficit
- Interventions
- TVS rehabilitation sessions
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Study whether adding tendon vibratory stimulation (TVS) to the usual rehabilitation sessions on the after upper limb after a stroke improves the recovery of the limb's motor strength. | T1: Right before the first rehabilitation session T2: After 5 rehabilitation sessions (up to 7 days) | Fugl Meyer Assesment (FMA) of the affected limb after 5 rehabilitation session (T2) with or without the TVS. FMA score ranges from 0 to 66, with 0 representing the most severe deficit and 66 representing normal motor function. |
| Secondary | Study the effect of adding TVS rehabilitation on the motor strength of the affected upper limb over time. | T1: Right before the first rehabilitation session T2: After 5 rehabilitation sessions (up to 7 days) T3: After 10 rehabilitation session (up to 25 days) or when the patient leaves (if before 10 sessions with a minimum of 8) | Motor strength of the affected upper limb scored by Shoulder Abduction and Finger Extension (SAFE) Score. The SAFE score is calculated by summing the MRC grades for shoulder abduction and finger extension. The total score ranges from 0 to 10, where 0 represents no voluntary muscle activity in shoulder abduction and finger extension and 10 represents normal strength in both movement. |
| Secondary | Study the effect of adding TVS rehabilitation on wrist motor strength over time. | T1: Right before the first rehabilitation session T2: After 5 rehabilitation sessions (up to 7 days) T3: After 10 rehabilitation session (up to 25 days) or when the patient leaves (if before 10 sessions with a minimum of 8) | Motor strength of the wrist (on the affected upper limb) is evaluated by subsection n°6 of the Fugl Meyer Assesment (FMA). Score ranges from 0 (severe impairment) to 6 (normal coordination and speed) |
| Secondary | Study the effect of adding TVS rehabilitation on finger grip strength over time. | T1: Right before the first rehabilitation session T2: After 5 rehabilitation sessions (up to 7 days) T3: After 10 rehabilitation session (up to 25 days) or when the patient leaves (if before 10 sessions with a minimum of 8) | Grip strength evaluated with a Jamar dynamometer (the value retained being the average of 3 tries). |
| Secondary | Study whether adding TVS rehabilitation improves the conscious deep sensitivity of the affected upper limb over time | T1: Right before the first rehabilitation session T2: After 5 rehabilitation sessions (up to 7 days) T3: After 10 rehabilitation session (up to 25 days) or when the patient leaves (if before 10 sessions with a minimum of 8) | Conscious deep sensitivity of the affected upper limb is evaluated by Thumb Localization Test (TLT). TLT ranges from 0 to 3, where 0 indicates normal thumb localization and 3 indicates severe proprioceptive impairment with inability to accurately locate the thumb. |
| Secondary | Study whether adding STV therapy reduces spasticity in the affected upper limb over time. | T1: Right before the first rehabilitation session T2: After 5 rehabilitation sessions (up to 7 days) T3: After 10 rehabilitation session (up to 25 days) or when the patient leaves (if before 10 sessions with a minimum of 8) | Spasticity is evaluated by modified Ashworth scale. This scale ranges from 0 (no increase in muscle tone) to 4 (affected part rigid in flexion or extension). |
| Secondary | Study whether adding STV therapy reduces pain in the affected upper limb over time | T1: Right before the first rehabilitation session T2: After 5 rehabilitation sessions (up to 7 days) T3: After 10 rehabilitation session (up to 25 days) or when the patient leaves (if before 10 sessions with a minimum of 8) | Pain in the affected upper limb is evaluated by Visual Analogue Scale (VAS). The VAS ranges from 0 to 10. 0 represents the worst pain and 10 represents no pain. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07905625
GET https://conductscience.org/api/trials/v1/NCT07905625/registered